Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials: Immunotherapy

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Jianming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequn Li, Xiaoming Chen, Zhiming Wang, Kangsheng Gu, Xi Chen, Zhanyu Pan, Kuansheng Ma, Xinmin Zhou, Zujiang Yu, Enxiao Li, Guowen Yin, Xiao Zhang, Shuni Wang and Quanren Wang
Jianming Xu
1Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jianming Xu
  • For correspondence: jmxu2003@yahoo.com
Jie Shen
2Department of Oncology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shanzhi Gu
3Radioactive Interventional Department, Hunan Cancer Hospital, Changsha, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yun Zhang
1Department of Gastrointestinal Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lihua Wu
4Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Wu
4Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guoliang Shao
5Intervention Therapy Department, Zhejiang Cancer Hospital, Hangzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanqiao Zhang
6Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Xu
7Hepatobiliary and Pancreatic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Li Xu
Tao Yin
8Department of Hepatic & Biliary & Pancreatic Surgery, Hubei Cancer Hospital, Affiliated Hubei Cancer Hospital of Huazhong University of Science and Technology, Wuhan, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingfeng Liu
9Liver Department, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhenggang Ren
10Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianping Xiong
11Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xianhai Mao
12Liver Surgery, Hunan People's Hospital, Changsha, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ling Zhang
13Hepatobiliary Surgery, Henan Cancer Hospital, Zhengzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiayin Yang
14Liver Transplantation Center, Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lequn Li
15Department of Hepatobiliary Surgery, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoming Chen
16Department of Interventional Radiology, Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhiming Wang
17General Surgery, Liver & Thyroid Surgery, Xiangya Hospital Central South University, Changsha, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kangsheng Gu
18Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xi Chen
19Medical Oncology, 900 Hospital of the Joint Logistics Support Force, Fuzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhanyu Pan
20Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuansheng Ma
21Hepatobiliary Surgery, The First Hospital Affiliated to AMU, Chongqing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinmin Zhou
22Digestive Department, The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zujiang Yu
23Infectious Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enxiao Li
24Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guowen Yin
25Interventional Department, Jiangsu Cancer Hospital, Nanjing, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiao Zhang
26Clinical Research & Development, Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuni Wang
26Clinical Research & Development, Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Quanren Wang
26Clinical Research & Development, Jiangsu Hengrui Medicine Co., Ltd, Shanghai, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-20-2571 Published February 2021
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.

Abstract

Purpose: We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).

Patients and Methods: This nonrandomized, open-label, multicenter, phase II study enrolled patients with advanced HCC who were treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received intravenous camrelizumab 200 mg (for bodyweight ≥50 kg) or 3 mg/kg (for bodyweight <50 kg) every 2 weeks plus oral apatinib 250 mg daily. The primary endpoint was objective response rate (ORR) assessed by an independent review committee (IRC) per RECIST v1.1.

Results: Seventy patients in the first-line setting and 120 patients in the second-line setting were enrolled. As of January 10, 2020, the ORR was 34.3% [24/70; 95% confidence interval (CI), 23.3–46.6] in the first-line and 22.5% (27/120; 95% CI, 15.4–31.0) in the second-line cohort per IRC. Median progression-free survival in both cohorts was 5.7 months (95% CI, 5.4–7.4) and 5.5 months (95% CI, 3.7–5.6), respectively. The 12-month survival rate was 74.7% (95% CI, 62.5–83.5) and 68.2% (95% CI, 59.0–75.7), respectively. Grade ≥3 treatment-related adverse events (TRAE) were reported in 147 (77.4%) of 190 patients, with the most common being hypertension (34.2%). Serious TRAEs occurred in 55 (28.9%) patients. Two (1.1%) treatment-related deaths occurred.

Conclusions: Camrelizumab combined with apatinib showed promising efficacy and manageable safety in patients with advanced HCC in both the first-line and second-line setting. It might represent a novel treatment option for these patients.

See related commentary by Pinato et al., p. 908

This article is featured in Highlights of This Issue, p. 903

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

  • ClinicalTrials.gov identifier: NCT03463876.

  • Clin Cancer Res 2021;27:1003–11

  • Received July 1, 2020.
  • Revision received September 7, 2020.
  • Accepted October 14, 2020.
  • Published first October 21, 2020.
  • ©2020 American Association for Cancer Research.
View Full Text

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
Clinical Cancer Research: 27 (4)
February 2021
Volume 27, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Jianming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequn Li, Xiaoming Chen, Zhiming Wang, Kangsheng Gu, Xi Chen, Zhanyu Pan, Kuansheng Ma, Xinmin Zhou, Zujiang Yu, Enxiao Li, Guowen Yin, Xiao Zhang, Shuni Wang and Quanren Wang
Clin Cancer Res February 15 2021 (27) (4) 1003-1011; DOI: 10.1158/1078-0432.CCR-20-2571

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Jianming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequn Li, Xiaoming Chen, Zhiming Wang, Kangsheng Gu, Xi Chen, Zhanyu Pan, Kuansheng Ma, Xinmin Zhou, Zujiang Yu, Enxiao Li, Guowen Yin, Xiao Zhang, Shuni Wang and Quanren Wang
Clin Cancer Res February 15 2021 (27) (4) 1003-1011; DOI: 10.1158/1078-0432.CCR-20-2571
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Authors' Disclosures
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Long-Term Follow-up of Immunotherapy for Neuroblastoma
  • Immunotherapy and Radiotherapy in Advanced Colorectal Cancer
  • Efficacy of Pembrolizumab for CPS 10 G/GEJ Cancer
Show more Clinical Trials: Immunotherapy
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement